Nutriband Inc. is developing a groundbreaking transdermal drug delivery system designed to address critical challenges in pain management and the ongoing opioid crisis. During a recent BioMedWire Podcast interview, CEO Gareth Sheridan highlighted the company's innovative AVERSA™ platform, which seeks to improve the safety of opioid patches while maintaining patient accessibility.
The pharmaceutical landscape has dramatically shifted in recent years, with the fentanyl patch market shrinking from $4 billion in 2016 to under $1 billion today. This contraction stems from increased liability concerns and stigma surrounding opioid medications, despite a persistent patient population requiring pain management solutions.
AVERSA™ represents a potential solution by implementing design features that make opioid patches difficult to manipulate for non-medical use. By deterring potential abuse, the platform could help restore prescriber and payer confidence in transdermal opioid therapies.
The development comes at a critical time when pain management strategies require innovative approaches that balance patient care with safety considerations. Nutriband's strategy addresses the complex challenges of providing effective pain relief while mitigating potential drug misuse risks.
